RNAZ
TransCode Therapeutics, Inc. - Common Stock (RNAZ)
$00
About TransCode Therapeutics, Inc. - Common Stock (RNAZ)
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Details
Daily high
$5.18
Daily low
$4.35
Price at open
$4.70
52 Week High
$20.99
52 Week Low
$3.82
Market cap
4.5M
Dividend yield
0.00%
Volume
11,628
Avg. volume
154,149
P/E ratio
-.10
TransCode Therapeutics, Inc. - Common Stock News
Details
Daily high
$5.18
Daily low
$4.35
Price at open
$4.70
52 Week High
$20.99
52 Week Low
$3.82
Market cap
4.5M
Dividend yield
0.00%
Volume
11,628
Avg. volume
154,149
P/E ratio
-.10